Ratings Qol Holdings Co., Ltd.

Equities

3034

JP3266160005

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-15 am EDT			5-day change	1st Jan Change
1,512 ^JPY	+0.07%		-17.74%	-8.75%

Mar. 19	Qol to Secure 25 Billion Yen Bank Loan	MT
Mar. 18	Qol Holdings Co., Ltd. Announces Notice of Borrowing (Refinancing) of Funds	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
The earnings growth currently anticipated by analysts for the coming years is particularly strong.
The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.35 for the 2024 fiscal year.
The company's share price in relation to its net book value makes it look relatively cheap.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company sustains low margins.

Ratings chart - Surperformance

Sector: Drug Retailers

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
QOL HOLDINGS CO., LTD.	-8.75%	360M		-
RAIA DROGASIL S.A.	-6.73%	9.04B		B
AIN HOLDINGS INC.	+32.41%	1.35B		-
NIHON CHOUZAI CO.,LTD.	+0.29%	271M		-
PETMED EXPRESS, INC.	-39.09%	98.61M		C
GREEN CROSS HEALTH LIMITED	-9.17%	85.69M	-	-
MEDICAL IKKOU GROUP CO.,LTD.	+20.94%	59.94M	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes